With Iveric Bio/Astellas promising ophthalmic approval of the only GA treatment in 2023, suprachoroidal delivery transforming gene therapy delivery to the back of the eye and sustained-release drug delivery methods showing promise for prolonged bioavailability for retinal targets, 2024 is set to be a big year for the ophthalmic delivery field thanks to rising investment and excitement for novel technology!
Designed alongside experts from Ophthalmic R&D from the likes of Genentech, Novartis, Everads Therapy, and AbbVie, this agenda will tackle preclinical and translational challenges when developing delivery devices, finding appropriate preclinical models, achieving sustained release of ocular drugs, and overcoming regulatory challenges with drug/device combinations in the eye.
What’s New for 2024?
|New content for device engineers to learn how you can tackle preclinical and translational challenges when developing drug delivery devices for your ophthalmic drugs, from suprachoroidal and intravitreal injections to sustained release implants and updates on subretinal surgery|
|Join AbbVie, Novartis, Genentech, Clearside Biomedical, and Opus Genetics as they deep dive in the brand-new workshop day with content split into Molecule R&D and Device R&D to ensure all bases are covered when discussing ocular drug and delivery device development|
|Exploring drug/device combination products with specific ophthalmic regulatory guidelines and understanding the basis of approval for different ophthalmic delivery administration routes|
Hear What Our Previous Attendees Have to Say:
“Very useful event to attend to stay current with the latest developments in the ophthalmic drug delivery world”
Director Combination Product, AbbVie
“Well organized event which convened SMEs in field of ophthalmic delivery and treatment field for knowledge and experience exchange”
Research Fellow, Vertex Pharmaceuticals